{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-029378","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.308485+00:00","generated_at":"2026-06-05T06:07:58.720283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Innoviva Q4 net income $61.5M, royalty revenue $69.6M; product sales up 35% YoY","bullets":["Q4 net income $61.5M ($0.97 EPS) vs $68.3M loss in Q4 2022; full-year net income $179.7M.","Q4 GSK royalty revenue $69.6M; net product sales $19.7M (+35% YoY) driven by GIAPREZA ($13.1M) and XERAVA ($5.2M).","Repurchased 1.1M shares for $15.4M in Q4; full-year repurchases $76.5M; $15M authorization remaining.","XACDURO approved for HABP/VABP; zoliflodacin met Phase 3 primary endpoint; NDA filing within 12 months.","Cash and receivables >$275M; strategic assets valued at $561M; invested $5M in Gate Neurosciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-029378","json":"https://secwatch.observer/filing/0001104659-24-029378.json","markdown":"https://secwatch.observer/filing/0001104659-24-029378.md","text":"https://secwatch.observer/filing/0001104659-24-029378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465924029378/0001104659-24-029378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465924029378/tm247467d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:07:58.720283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"148d5abe9c315c66ba252ae7fe3084a00eae1fb5","claim":"Innoviva, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net income was $61.5 million, or $0.97 basic per share.","evidence_excerpt":"On February 29, 2024, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1080014/000110465924029378/0001104659-24-029378-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"net income was $61.5 million, or $0.97 basic per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}